Drugs | Molecule Function | Effect on Disease or Function | Disease or Function | Causal or Correlated | Findings |
Atabecestat | BACE Inhibitor | decreases | AD | Causal | 1 |
Bapineuzumab | IgG1 that binds soluble/fibrillar Aβ | decreases | AD | Causal | 7 |
BAN2401 | IgG1 that binds Aβ protofibrils | decreases | Early Stage AD | Causal | 1 |
Crenezumab | IgG4 that binds Aβ peptides, oligomers, fibrils and has low affinity for monomers | decreases | AD, Mild AD, Prodromal AD | Causal | 4 |
Elenbecestat | BACE inhibitor | decreases | Mild AD | Causal | 1 |
Gantenerumab | IgG1 that binds Aβ fibrils | decreases | AD, Early Stage AD, Familial AD, Mild AD, Prodromal AD | Causal | 6 |
Lanabecestat | BACE1 inhibitor | decreases | AD | Causal | 3 |
Latrepiridine | Antihistamine that modulates neurotransmitters and block Aβ-mediated toxicity | decreases | AD | Causal | 7 |
Semagacestat | γ-secretase inhibitor | decreases | AD | Causal | 3 |
SK-PC-B70M | Protects against Aβ-mediated toxicity | decreases | AD | Causal | 1 |
Solanezumab | IgG1 that binds Aβ peptides and monomers | decreases | AD, Familial AD, Prodromal AD | Causal | 7 |
Tarenflurbil | NSAID R-enantiomer that modulates γ-secretase activity to reduce Aβ aggregate formation | decreases | AD | Causal | 2 |
Tramiprosate | Taurine derivative that prevents Aβ β-sheet formation | decreases | AD | Causal | 3 |